MINK THERAPEUTICS, INC.
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Find out what a historical investment in MINK THERAPEUTICS, INC. would be worth today using our INKT stock calculator.
$33.71M
-
0.00%
7.03K
$9.23
$8.80
$8.82
$19.00
$4.56
Ready to start your investing journey with Stake?
Open an accountINKT FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in INKT
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in INKT
on Stake
Buy INKT from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of INKT from only US$10 with fractional shares
